Journal
JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES
Volume 51, Issue 5, Pages 513-521Publisher
LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1097/QAI.0b013e3181b16d00
Keywords
ADAP; AIDS; anti-HIV agents*/therapeutic use; CD4 lymphocyte count; government programs; resource allocation
Categories
Funding
- NIAID NIH HHS [K24AI062476, R37 AI042006, R37 AI042006-13, K24 AI062476-01, R37AI42006, P30 AI060354, K01AI073193, K24 AI062476, K01 AI073193-02, K01 AI073193, P30AI060354] Funding Source: Medline
- NIMH NIH HHS [R01MH073445, R01 MH073445] Funding Source: Medline
Ask authors/readers for more resources
Background: State AIDS Drug Assistance Programs (ADAPs) provide antiretroviral medications to patients with no acccss to medications. Resource constraints limit the ability of many ADAPs to meet demand for services. Objective: To determine ADAP eligibility criteria that minimize morbidity and mortality and contain costs. Methods: We used Discrete Event Simulation to model the progression of HIV-infected patients and track the utilization of all ADAP. Outcomes included 5-year mortality and incidence of first opportunistic infection or death and time to starting antiretroviral therapy (ART). We compared expected outcomes for 2 policies: (1) first-come first-served (FCFS) eligibility for all with CD4 Count <= 350/mu L (current standard) and (2) CD4 Count prioritized eligibility for those with CD4 counts below a defined threshold. Results: In the base case, prioritizing patients with CD4 counts <= 250/mu L led to lower 5-year mortality than FCFS eligibility (2.77 vs. 3.27 deaths per 1000 person-months) and to a lower incidence of first Opportunistic infection or death (5.55 vs. 6.98 events per 1000 person-months). CD4-based eligibility reduced the time to starting ART for patients with CD4 Counts :<= 200/mu L. In sensitivity analyses, CD4-based eligibility consistently led to lower morbidity and mortality than FCFS eligibility. Conclusion: When resources are limited, programs that provide ART call improve Outcomes by prioritizing patients with low CD4 Counts.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available